<DOC>
	<DOCNO>NCT00364221</DOCNO>
	<brief_summary>The metabolic syndrome collection health risk include obesity , high blood pressure , high triglyceride , high blood sugar , low good cholesterol , resistance insulin . The purpose study find medication , rosiglitazone , influence level fat cell protein alters insulin resistance nondiabetic person metabolic syndrome . This early step see medication , rosiglitazone , beneficial people metabolic syndrome .</brief_summary>
	<brief_title>Effect Rosiglitazone Nondiabetic Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Nondiabetic subject NCEP/ATP III diagnosis metabolic syndrome Statin Medications , liver disease , cardiovascular disease , heart failure , diabetes , chronic kidney disease ,</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>